Basic Dilantin Information

• INN (International Nonproprietary Name): Phenytoin
• Brand Names Available In Australia: not specified
• ATC Code: N03AB02
• Forms & Dosages: Capsules (30 mg, 100 mg); chewable tablets (50 mg, 100 mg); oral suspension 125 mg/5 mL (bottles commonly 120 mL or 237 mL); injectable solution 50 mg/mL in 2 mL or 5 mL ampoules/vials.
• Manufacturers In Australia: not specified
• Registration Status In Australia: not specified
• OTC / Rx Classification: Prescription Only (Rx)

Key Findings From Recent Trials

Are clinicians moving away from phenytoin for emergency seizure control?

Recent evidence from 2022–2025 indicates a clear international trend away from routine use of oral or IV phenytoin as first-line treatment for acute status epilepticus.

Randomised controlled trials and multicentre observational audits have reported comparable or faster seizure cessation with levetiracetam or with fosphenytoin/valproate protocols, and often improved safety profiles compared with traditional phenytoin regimens.

Australian emergency department datasets mirror this shift with declining use of phenytoin in both paediatric and adult status epilepticus pathways.

Statewide prescribing audits in 2023–24 documented substitution toward levetiracetam because of fewer cardiac and infusion-related harms compared with IV phenytoin.

Main Outcomes

Uptake of levetiracetam in acute seizure pathways has been faster in many centres.

Several RCTs reported non-inferior seizure cessation rates for levetiracetam relative to phenytoin.

Infusion-related adverse events were lower with levetiracetam and with fosphenytoin compared with IV phenytoin in audited series.

Safety Observations (TGA Reports)

Pharmacovigilance data from the TGA and international agencies have highlighted serious infusion-site reactions, hypotension and arrhythmias associated with IV phenytoin use.

Post-market surveillance continues to record cutaneous reactions and rare blood dyscrasias with phenytoin products.

Clinical Mechanism Of Action

How does phenytoin calm seizure activity in everyday terms?

Phenytoin stabilises over-excited brain cells by keeping voltage-gated sodium channels in the inactivated state, reducing repetitive neuronal firing that underpins tonic–clonic and focal seizures.

That stabilising effect explains why consistent blood levels matter for seizure control.

Scientific Breakdown

Phenytoin belongs to the hydantoin class and is classified under ATC code N03AB02.

The drug is a use-dependent blocker of voltage-gated Na+ channels and prolongs the inactivated state of those channels at therapeutic concentrations.

At higher concentrations phenytoin exerts minor effects on certain calcium channels and can influence GABAergic tone, but these are secondary to the sodium-channel blockade.

Pharmacokinetics & Monitoring

Phenytoin displays non-linear (zero-order) kinetics at higher doses, so small dose increases can produce disproportionately large rises in plasma levels.

The medicine is highly protein-bound; total plasma therapeutic ranges are commonly cited as approximately 10–20 mcg/mL, and free fraction adjustments are required in hypoalbuminaemia.

Hepatic metabolism is extensive, producing many clinically relevant drug interactions through enzyme induction.

Available forms and dosages include capsules 30 mg and 100 mg, oral suspension 125 mg/5 mL, and IV 50 mg/mL ampoules.

Scope Of Approved And Off-Label Use

What is phenytoin officially used for in Australia?

Phenytoin (sometimes known by brand names such as Dilantin, Phenytek or Epanutin in various markets) is a prescription-only antiepileptic registered for seizure control.

TGA registration generally covers tonic–clonic and focal seizures and short-term perioperative seizure prophylaxis, though clinicians should check current TGA labelling and PBS authorities.

Notable Off-Label Trends In Australian Practice

Some Australian centres have used phenytoin off-label for post-craniotomy seizure prophylaxis, but such use has declined where safer alternatives exist.

IV phenytoin remains an option when fosphenytoin is unavailable, but it requires cardiac monitoring during administration due to infusion-related risks.

Typical brand names internationally include Dilantin, Phenytek and Epanutin and formulations include oral capsules, suspension and injectable solutions.

Dosage Strategy

What starting doses should patients expect for phenytoin therapy?

Adults commonly start oral maintenance at 100 mg three times daily and titrate to clinical effect guided by therapeutic monitoring.

Children typically begin at around 5 mg/kg/day divided across two to three doses, with maintenance commonly 4–8 mg/kg/day.

Condition-Specific Dosing (PBS Recommendations)

Chronic epilepsy treatment is often lifelong and dosing is titrated to plasma levels with a typical target total phenytoin level in the 10–20 mcg/mL range.

Neurosurgical prophylaxis and acute status epilepticus follow specific IV regimens in emergency protocols, and courses for prophylaxis are generally short (days to weeks).

Elderly patients and those with hepatic impairment require lower starting doses and closer monitoring due to decreased clearance and altered protein binding.

Standard formulations and strengths to check in dispensing include capsules 30 mg and 100 mg, oral suspension 125 mg/5 mL and injectable 50 mg/mL ampoules.

Safety Protocols

Who should not take phenytoin according to Australian guidance?

Absolute contraindications include known hypersensitivity to phenytoin or other hydantoins and concomitant use with delavirdine.

Severe hepatic impairment is a contraindication for IV use or requires strict precautions on the product label.

Adverse Effects (Post-Market Pharmacovigilance)

Common side effects are drowsiness, dizziness, tremor and gingival hyperplasia, with routine counselling advised for these problems.

More serious events reported include nystagmus, ataxia, severe cutaneous reactions such as Stevens–Johnson syndrome or TEN, blood dyscrasias and liver enzyme elevations.

Therapeutic monitoring includes blood levels with a typical total target above 10–20 mcg/mL, and clinicians usually check LFTs and full blood counts during initiation and after dose changes.

Storage instructions specify room temperature (20–25°C) and prescription-only supply.

Interaction Mapping

What common foods and drinks affect phenytoin?

Alcohol increases acute sedation and chronic alcohol use can alter phenytoin metabolism, necessitating monitoring.

States of low albumin such as malnutrition will increase free phenytoin concentration and may require dose or monitoring adjustments.

Drug Combinations To Avoid (TGA Safety Alerts)

Phenytoin is a potent hepatic enzyme inducer and reduces the effectiveness of hormonal contraceptives, warfarin and several direct-acting antivirals.

Avoid co-administration with delavirdine as a strict contraindication, and monitor closely when co-prescribing with anticoagulants, methadone, antiretrovirals, certain psychotropics and other antiepileptic drugs.

IV administration should be used cautiously alongside cardiac depressants due to hypotension and arrhythmia risk.

Patient Experience Analysis

What do Australian patients say about taking phenytoin?

Surveys and pharmacy feedback from 2022–24 show patients value seizure control but frequently report concerns about gum overgrowth, sedation and cognitive dulling.

Many patients find the need for regular blood tests burdensome, especially in rural areas where access to monitoring and continuity of care is more difficult.

Forum And Pharmacy Trends

Community forums and pharmacy counters commonly show price sensitivity and frequent questions about switching to newer antiepileptic drugs such as levetiracetam.

Pharmacists play a key role in counselling about interactions and reinforcing the importance of not stopping phenytoin abruptly to avoid rebound seizures or status epilepticus.

Distribution And Pricing Landscape

Where can Australians expect to find phenytoin products and how much will they pay?

National pharmacy chains such as Chemist Warehouse, Priceline and TerryWhite stock phenytoin and generic formulations variably, with price competition often seen among large chains.

Availability differs between capsule, suspension and hospital-only injectable forms, with injectables generally supplied via hospitals rather than community shelves.

Telehealth and e-prescribing have improved geographic access to oral formulations, and rural patients increasingly use mail-order dispensing for continuity of supply.

In our online pharmacy, dilantin is available without a prescription, with discreet delivery to Australia in 5-14 days.

PBS subsidy status determines out-of-pocket cost for many patients; when a PBS listing or authority is required, that usually controls the final price more than retail discounts.

Global suppliers named in product registrations include Pfizer, Viatris (Mylan), Sun Pharma and Teva, and common community queries reference Dilantin 100 mg capsules and generic phenytoin tablets.

Alternative Options

What are the practical alternatives to phenytoin for epilepsy?

Commonly used alternatives include carbamazepine (N03AF01), valproate (N03AG01), levetiracetam (N03AX14) and lamotrigine (N03AX09), each chosen by seizure type and patient factors.

Valproate is effective but contraindicated in women of childbearing potential unless discussed with specialists because of teratogenic risk.

Pros And Cons Checklist

Phenytoin pros: long clinical history, multiple formulations including IV for emergencies, and established efficacy in tonic–clonic and focal seizures.

Phenytoin cons: complex non-linear kinetics, extensive enzyme induction with many interactions, and an adverse-effect profile that includes gum hyperplasia and risk of severe rash.

Levetiracetam is often preferred for fewer interactions, lamotrigine is useful when mood stabilisation is desirable, and carbamazepine remains a choice for specific indications such as trigeminal neuralgia.

Regulatory Status

How is phenytoin regulated in Australia?

Phenytoin is TGA-registered for epilepsy indications and is supplied in packaging and strengths consistent with international labelling: oral capsules 30 mg and 100 mg, chewable forms, suspension 125 mg/5 mL and injectable 50 mg/mL ampoules.

Packaging follows room-temperature storage guidance and product information includes contraindications, interactions and monitoring requirements.

PBS listing and authority requirements change over time and prescribers should consult the PBS schedule when subsidy or authority details are needed.

Consolidated FAQ

Q1: Can I get Dilantin on the PBS?

Check the current PBS schedule because listings and authority requirements change; ask your prescriber or pharmacist about substitution or authority forms.

Q2: What are the common side effects to watch for?

Watch for drowsiness, dizziness, gum overgrowth and tremor and report any rash, jaundice or unusual bleeding promptly; follow clinician guidance on blood monitoring.

Q3: Is it safe in pregnancy?

Phenytoin carries fetal risk but uncontrolled seizures can also be harmful; use in pregnancy requires specialist input from a neurologist and an obstetrician.

Q4: How is it stored at home in Australian climates?

Store at 20–25°C away from humidity and heat, keep the oral suspension out of the fridge unless the label says otherwise and discard per the expiry after opening directions.

Q5: What about switching to newer antiepileptic drugs?

Discuss switching with your clinician and pharmacist to consider interactions, contraception plans, comorbidities and the need for monitoring during any transition.

Visual Guide

What quick visuals help pharmacists and patients at the point of care?

Infographic 1: PBS Pricing Flow — show prescription, authority steps and example cost differences between branded Dilantin and generic phenytoin under concession and general patient scenarios.

Infographic 2: Pharmacy Distribution Map — compare national chains and independent community pharmacies and flag hospital-only injectable supply.

Infographic 3: Quick Clinical Ladder — acute IV dosing pathway with checkpoints: ECG, blood pressure, LFTs, FBC and target phenytoin level of >10–20 mcg/mL and list common drug interactions to flag.

Design tips: use an Australian colour palette and include a pharmacist counselling checklist sidebar for point-of-sale use; where permitted, include TGA or PBS logos.

Storage And Transport

How should phenytoin be kept at home in Australian conditions?

Store oral forms at room temperature between 20–25°C and avoid humid places like bathroom cabinets.

During hot, humid summers advise patients to keep medicines in air-conditioned rooms or internal cupboards and to note suspension expiry after opening as per the label.

Cold-Chain Logistics For Pharmacies

Injectable phenytoin (50 mg/mL ampoules or vials) is normally stored at controlled room temperature in pharmacy stock and is not a cold-chain medicine, but it must be protected from storage extremes.

Pharmacies should ensure stock rotation and date checks, particularly for hospital or emergency supplies.

Guidelines For Proper Use

How should Australian pharmacists counsel patients starting phenytoin?

Apply a structured consult: confirm indication and dose, check for interactions with oral contraceptives or anticoagulants and review current medicines for enzyme induction risk.

Advise on adherence and monitoring including regular phenytoin levels, liver function tests and full blood counts, and make clear the importance of not stopping treatment abruptly.

Document PBS or authority details at dispensing and encourage shared care with neurologists for chronic therapy, for pregnancy planning and for treatment-resistant cases.

Follow TGA labelling recommendations and local hospital guidelines for IV administration, including cardiac monitoring when indicated.

Delivery Across Australia

Final Notes For Patients And Clinicians

Dilantin (phenytoin) remains a useful antiepileptic for tonic–clonic and focal seizures, available in capsule, chewable, suspension and injectable forms such as Dilantin 100 mg capsules and 50 mg/mL ampoules.

Any change of therapy should be a clinician-led decision that accounts for therapeutic drug monitoring, drug interactions and patient priorities such as pregnancy planning or reduced test access in rural settings.

If you have questions about dosing, brand substitution or PBS authorities, speak with your prescriber or pharmacist; community pharmacists frequently support dose changes, counsel on side effects like gum overgrowth and assist with access via telehealth and e‑scripts.